Persistent genital tract HIV-1 RNA shedding after change in treatment regimens in antiretroviral-experienced women with detectable plasma viral load

Journal of Women's Health

Volumn 22, Issue 4, 2013, Pages 330-338

  Venkatesh, Kartik K ^a   Delong, Allison K ^a   Kantor, Rami ^b   Chapman, Stacey ^b   Ingersoll, Jessica ^c   Kurpewski, Jaclynn ^b   De Pasquale, Maria Pia ^d   D'Aquila, Richard ^e   Caliendo, Angela M ^d   Cu Uvin, Susan ^a,b  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR; GENITAL TRACT HUMAN IMMUNODEFICIENCY VIRUS 1 RNA; LAMIVUDINE; LOPINAVIR; NELFINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNCLASSIFIED DRUG; VIRUS RNA; ZIDOVUDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LONGITUDINAL STUDY; PLASMA VIRAL LOAD; PRIORITY JOURNAL; PROSPECTIVE STUDY; VIRUS LOAD; VIRUS SHEDDING;

ADOLESCENT; ADULT; AGE FACTORS; CARDIOVASCULAR DISEASES; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MASS SCREENING; NORTH CAROLINA; POVERTY AREAS; PREGNANCY; REPRODUCTIVE HEALTH; RISK FACTORS;

EID: 84876276193     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2012.3849     Document Type: Article

References (35)

1. Anderson A, Bartlett JA. Changing antiretroviral therapy in the setting of virologic relapse: review of the current litera-ture. Curr HIV/AIDS Rep 2006;3:79-85.
2. Dumond JB, Yeh RF, Patterson KB, et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS 2007;21:1899-1907.
3. von Wyl V, Yerly S, Bürgisser P et al. Swiss HIV cohort study: long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced pa-tients in Switzerland. Clin Infect Dis 2009;48:979-987.
4. Taylor S, Cane P, Workman J,et al. Identification of a transmission chain of HIV-1 drug resistant virus. AIDS Res Hum Retroviruses 2003;19:353-361.
5. Little S, Holte S, Routy JP, et al. Antiretroviral-drug resis-tance among patients recently infected with HIV. New Engl J Med 2002;347:385-394.
6. Grant R, Hecht FM, Warmerdam M,et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002;288:181-188.
7. TC, Wawer MJ, Sewankambo N, et al. Viral load and het-erosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. New Engl J Med 2000;342:921-929.
8. Mofenson L, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. New Engl J Med 1999;341:385-393.
9. Kalichman S, Di Berto G, Eaton L. Human immunodefi-ciency virus viral load in blood plasma and semen: review and implications of empirical findings. Sex Trans Dis 2008;35:55-60.
10. Anton P, Herold BC. HIV transmission: time for translational studies to bridge the gap. Sci Transl Med 2011;3:77ps11.
11. Cu-Uvin S, Caliendo AM, Reinert S, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS. 2000;14:415-421.
12. Cu-Uvin S, Snyder B, Harwell JI, et al. Association between paired plasma and cervicovaginal lavage fluid HIV-1 RNA levels during 36 months. J Acquir Immune Defic Syndr 2006;42:584-587.
13. Cu-Uvin S, DeLong AK, Venkatesh KK, et al. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS 2010;24:2489-2497
14. Kovacs A, Wasserman SS, Burns D, et al.; DATRI study group; WIHS study group. Determinants of HIV-1 shedding in the genital tract of women. Lancet 2001;358:1593-1601.
15. Neely MN, Benning L, Xu J, et al. Cervical shedding of HIV-1 RNA among women with low levels of viremia while re-ceiving highly active antiretroviral therapy. J Acquir Im-mune Defic Syndr 2007;44:38-42.
16. Homans J, Christensen S, Stiller T, et al. Permissive and protective factors associated with presence, level, and lon-gitudinal pattern of cervicovaginal HIV shedding. J Acquir Immune Defic Syndr 2012;60:99-110.
17. Asin S, Eszterhas SK, Rollenhagen C, Heimberg AM, Howell AL. HIV type 1 infection in women: increased transcription of HIV type 1 in ectocervical tissue explants. J Infect Dis 2009;200:965-972.
18. Cu-Uvin S, DeLong AK, Venkatesh KK, et al. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS 2010;24:2489-2497
19. Fideli U, Allen SA, Musonda R, et al. Virologic and immu-nologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses 2001;17:901-910.
20. Tovanabutra S, Robison V, Wongtrakul J, et al. Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr 2002;29:275-283.
21. Donnell D, Baeten JM, Kiarie J, et al.; Partners in Prevention HSV/HIV Transmission Study Team. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010;375:2092-2098.
22. Montaner J, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010;376:532-539.
23. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV in-fections in San Francisco. PLoS One. 2010;5:e11068.
24. Baeten J, Kahle E, Lingappa JR, et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med 2011;3:77ra29.
25. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493-505.
26. Cohen M, Gay C, Kashuba AD, Blower S, Paxton L. Nar-rative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007;146:591-601.
27. Kemal K, Burger H, Mayers D, Anastos K, Foley B, Kitchen C, Huggins P, Schroeder T, Picchio G, Back S, Gao W, Meyer WA 3rd, Weiser B. HIV-1 drug resistance in variants from the female genital tract and plasma. Journal of Infectious Disease. 2007;195(4):535-545.
28. Johnson V, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010;18:156-163.
29. Nagot N, Ouedraogo A, Weiss HA,et al.; Yerelon Study Group. Longitudinal effect following initiation of highly active antiretroviral therapy on plasma and cervico-vaginal HIV-1 RNA among women in Burkina Faso. Sex Transm Infect 2008;84:167-170.
30. Graham S, Holte SE, Peshu NM, et al. Initiation of anti-retroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS 2007;21:501-507
31. Andreoletti L, Skrabal K, Perrin V, Chomont N, Saragosti S, Gresenguet G, Moret H, Jacques J, Longo Jde D, Matta M, Mammano F, Belec L. Genetic and phenotypic features of blood and genital viral populations of clinically asymp-tomatic and antiretroviral-treatment-naive clade a human immunodeficiency virus type 1-infected women. J Clin Mi-crobiol 2007;45:1838-1842.
32. Chomont N, Hocini H, Grésenguet G, et al. Early archives of genetically-restricted proviral DNA in the female genital tract after heterosexual transmission of HIV-1. AIDS 2007;21:153-162.
33. Kwara A, Delong A, Rezk N, et al. Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active anti-retroviral therapy. Clin Infect Dis 2008;46:719-725.
34. Kantor R, Wantman M, Katzenstein D, et al.; ACTG A5077 Study Team. Viral shedding and drug resistance in plasma and genital compartments among viremic, multi-drug-experienced HIV-infected men and women. Paper presented at 15th Conference on Retroviruses and Opportunistic In-fections (CROI), Boston, MA, February 2008.
35. Katzenstein D, Winters M, Fiscus S, et al; AIDS Clin Trials Group 5077. Drug resistance in plasma and genital compart-ments among viremic, multi-drug-experienced men and wo-men. Paper presented at 13th Conference on Retroviruses and Opportunistic Infections (CROI), Denver, CO, February 2006.